Antitumor necrosis factor α is more effective than conventional medical therapy for the prevention of postoperative recurrence of Crohn's disease: A meta-analysis

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 10, 2014, Pages 1152-1159

  Nguyen, Douglas L ^a   Solaimani, Pejman ^a   Nguyen, Emily T ^b   Jamal, Mohammad Mazen ^c   Bechtold, Matthew L ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^d University of Missouri   (United States)

Author keywords

Anti tumor necrosis factor ; Crohn's disease; Postoperative prevention

Indexed keywords

ADALIMUMAB; INFLIXIMAB; MESALAZINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CINAHL; COCHRANE LIBRARY; CROHN DISEASE; DRUG EFFICACY; HUMAN; MANTEL HAENSZEL TEST; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REMISSION; SCOPUS; ANTAGONISTS AND INHIBITORS; CHI SQUARE DISTRIBUTION; GASTROINTESTINAL ENDOSCOPY; IMMUNOLOGY; PROCEDURES; RISK; RISK FACTOR; SECONDARY PREVENTION; TIME; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; CHI-SQUARE DISTRIBUTION; CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; GASTROINTESTINAL AGENTS; HUMANS; ODDS RATIO; RECURRENCE; RISK FACTORS; SECONDARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84927691904     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000178     Document Type: Article

References (34)

1. Latella G, Rogler G, Bamias G, Breynaert C, Florholmen J, Pellino G, et al. Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD. J Crohns Colitis 2014; pii:S1873-9946(14) 00120-S1873-9946(14)00122.
2. D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106:199-212.
3. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002; 359:1541-1549.
4. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54:237-241.
5. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000; 231:38-45.
6. Lazarev M, Ullman T, Schraut WH, Kip KE, Saul M, Regueiro M. Small bowel resection rates in Crohn's disease and the indication for surgery over time: experience from a large tertiary care center. Inflamm Bowel Dis 2010; 16:830-835.
7. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114:262-267.
8. Olaison G, Smedh K, Sjödahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992; 33:331-335.
9. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99:956-983.
10. Sachar DB. The problem of postoperative recurrence of Crohn's disease. Med Clin North Am 1990; 74:183-188.
11. Bougen G, Peyrin-Biroulet L. Surgery for adult Crohn's disease: what is the actual risk? Gut 2011; 60:1178-1181.
12. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV Jr. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol 2012; 107:1693-1701.
13. Michelassi F, Balestracci T, Chappel R, Block GE. Primary and recurrent Crohn's disease. Experience with 1379 patients. Ann Surg 1991; 214:230-238.
14. Buisson A, Chevaux JB, Allen PB, Bommelaer G, Peyrin-Biroulet L. Review article: the natural history of postoperative Crohn's disease recurrence. Aliment Pharmacol Ther 2012; 35:625-633.
15. Araki T, Uchida K, Okita Y, Fujikawa H, Inoue M, Ohi M, et al. The impact of postoperative infliximab maintenance therapy on preventing the surgical recurrence of Crohn's disease: a single-center paired case-control study. Surg Today 2014; 44:291-296.
16. Armuzzi A, Felice C, Papa A, Marzo M, Pugliese D, Andrisani G, et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study. J Crohns Colitis 2013; 7:e623-e629.
17. Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136:441.e1-450.e1.
18. Savarino E, Bodini G, Dulbecco P, Assandri L, Bruzzone L, Mazza F, et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. Am J Gastroenterol 2013; 108:1731-1742.
19. Sorrentino D, Terrosu G, Avellini C, Maiero S. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med 2007; 167:1804-1807.
20. Sorrentino D, Terrosu G, Paviotti A, Geraci M, Avellini C, Zoli G, et al. Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab - a pilot study. Dig Dis Sci 2012; 57:1341-1348.
21. Yamamoto T, Umegae S, Matsumoto K. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study. Inflamm Bowel Dis 2009; 15:1460-1466.
22. Yoshida K, Fukunaga K, Ikeuchi H, Kamikozuru K, Hida N, Ohda Y, et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm Bowel Dis 2012; 18:1617-1623.
23. Armijo-Olivo S, Stiles CR, Hagen NA, Biondo PD, Cummings GG. Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research. J Eval Clin Pract 2012; 18:12-18.
24. Regueiro M, Kip KE, Baidoo L, Swoger JM, Schraut W. Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence. Clin Gastroenterol Hepatol 2014; pii:S1542-3565(14)00053-S1542-3565(14) 00056.
25. Thomas BH, Ciliska D, Dobbins M, Micucci S. A process for systematically reviewing the literature: providing the research evidence for public health nursing interventions. Worldviews Evid Based Nurs 2004; 1:176-184.
26. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141:1194-1201.
27. Beppu T, Ono Y, Matsui T, Hirai F, Yano Y, Takatsu N, et al. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease. Dig Endosc 2014 [Epub ahead of print].
28. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012; 61:1619-1635.
29. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, et al. Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138:463-468.
30. Kiesslich R, Duckworth CA, Moussata D, Gloeckner A, Lim LG, Goetz M, et al. Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut 2012; 61:1146-1153.
31. Rutgeerts P. Strategies in the prevention of post-operative recurrence in Crohn's disease. Best Pract Res Clin Gastroenterol 2003; 17:63-73.
32. McLeod RS, Wolff BG, Steinhart AH, Carryer PW, O'Rourke K, Andrews DF, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology 1995; 109:404-413.
33. Peyrin-Biroulet L, Deltenre P, Ardizzone S, D'Haens G, Hanauer SB, Herfarth H, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009; 104:2089-2096.
34. Ananthakrishnan AN, Hurr C, Juillerat P, Korzenik JR. Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis. Am J Gastroenterol 2011; 106:2009-2017.